Update on the Treatment of Medullary Thyroid Carcinoma in Patients with Multiple Endocrine Neoplasia Type 2

Autor: Sophia Khan, Maran Ilanchezhian, Christian Okafor, Jaydira Del Rivero, John Glod
Rok vydání: 2020
Předmět:
medicine.medical_specialty
endocrine system diseases
Cabozantinib
Medullary cavity
Endocrinology
Diabetes and Metabolism
Clinical Biochemistry
Multiple Endocrine Neoplasia Type 2a
030209 endocrinology & metabolism
Multiple endocrine neoplasia type 2
Vandetanib
Proto-Oncogene Mas
Biochemistry
Thyroid carcinoma
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Endocrinology
Internal medicine
medicine
Humans
Thyroid Neoplasms
Protein Kinase Inhibitors
business.industry
Proto-Oncogene Proteins c-ret
Biochemistry (medical)
Thyroid
Disease Management
General Medicine
Prognosis
medicine.disease
Combined Modality Therapy
Carcinoma
Neuroendocrine
medicine.anatomical_structure
chemistry
Calcitonin
030220 oncology & carcinogenesis
Mutation
Thyroidectomy
Cancer research
business
Tyrosine kinase
medicine.drug
Zdroj: Hormone and Metabolic Research. 52:588-597
ISSN: 1439-4286
0018-5043
Popis: Medullary Thyroid Carcinoma (MTC) is a rare neuroendocrine cancer that accounts for 1–2% of thyroid cancers in the United States (U.S.). While most cases are sporadic, 25% of MTC cases are hereditary. These hereditary cases occur in the setting of Multiple Endocrine Neoplasia Type 2A (MEN2A) or 2B (MEN2B) driven by mutations in the Rearranged during Transfection RET proto-oncogene. This article discusses hereditary MTC in the setting of MEN2 and the treatment options available for it. The first line treatment for this disease is typically a total thyroidectomy and tyrosine kinase inhibitors. Two tyrosine kinase inhibitors, vandetanib and cabozantinib, have been approved for treatment of advanced MTC, but options beyond those are limited. However, several promising treatments are being studied, which are discussed in this review.
Databáze: OpenAIRE
Externí odkaz: